On this page
Cowden syndrome
People with Cowden syndrome develop numerous benign tumours called hamartomas throughout the body, alongside a markedly elevated lifetime risk of breast, thyroid, endometrial, and other cancers. The condition follows an autosomal dominant inheritance pattern and is caused by pathogenic variants in the PTEN gene.
Available at Jeen Health
Clinical tests that include this
Overview
Cowden syndrome is a genetic condition that predisposes affected individuals to developing multiple benign growths throughout the body, termed hamartomas, as well as substantially elevated risks for several types of cancer. The syndrome was first described in 1963 and named after the original patient, Rachel Cowden. Prevalence estimates suggest the condition affects approximately 1 in 200,000 individuals, though the true frequency may be higher due to underdiagnosis of milder presentations.
The hallmark features include characteristic skin findings such as multiple small papules on the face and hands, thickened skin on the palms and soles, and benign growths in various organs including the thyroid, breast, and gastrointestinal tract. However, the clinical significance of Cowden syndrome lies primarily in the substantially increased cancer risks, which require lifelong surveillance and risk-reducing strategies. The condition affects both men and women, though certain cancer risks such as breast and endometrial cancer are sex-specific. Most individuals with Cowden syndrome are identified through clinical genetics services after developing characteristic features or when family history prompts genetic evaluation.
Cowden syndrome forms part of a broader spectrum of related conditions sharing the same genetic basis. Early recognition and diagnosis enable appropriate cancer surveillance protocols through the NHS Genomic Medicine Service, potentially improving outcomes through early detection or risk reduction interventions. Genetic counselling plays an essential role in helping affected individuals and their families understand inheritance patterns, cancer risks, and available management options.
Symptoms & clinical features
The clinical features of Cowden syndrome typically emerge during late childhood or early adulthood, though some signs may appear earlier or later. Skin manifestations are among the most recognisable features, with the majority of affected individuals developing multiple small flesh-coloured papules called trichilemmomas on the face, particularly around the nose, mouth, and ears. These benign hair follicle tumours are considered highly characteristic of the condition. Many people also develop papillomatous papules on the hands, feet, and oral mucosa, alongside thickened, pebbled skin on the palms and soles termed acral keratoses.
Benign growths affecting internal organs are common and may include thyroid nodules, uterine fibroids, lipomas, and gastrointestinal polyps. Macrocephaly, defined as a head circumference above the 97th centile, occurs in a substantial proportion of affected individuals and may be present from childhood. Some people experience developmental concerns including intellectual disability or autism spectrum features, though cognitive function is typically normal in most cases. Breast tissue changes are frequent in women with Cowden syndrome, including fibrocystic changes and multiple benign breast masses, which can complicate cancer surveillance. The constellation of features varies considerably between individuals, even within the same family, making clinical recognition challenging without awareness of the characteristic pattern. Symptoms related to the various cancer types associated with Cowden syndrome depend on the specific tumour type and location, emphasising the importance of structured surveillance programmes for early detection.
Video: Is cancer in your genes?
Affected organs
Cowden syndrome can affect multiple organ systems throughout the body, reflecting the widespread expression of the PTEN gene in normal tissues. The skin is invariably involved, serving as an important diagnostic clue through the characteristic papules and thickened areas. The thyroid gland is affected in the majority of individuals, with benign nodular changes occurring frequently and thyroid cancer developing in a significant subset. Breast tissue is commonly affected in women, with both benign proliferative changes and substantially elevated cancer risk.
The gastrointestinal tract often harbours multiple hamartomatous polyps, particularly in the colon, though these generally carry lower malignant potential compared to polyps in other inherited cancer syndromes. The endometrium in women may develop both benign changes and carries increased cancer risk. The central nervous system can be affected, with some individuals developing a characteristic brain abnormality called Lhermitte-Duclos disease, which represents a slowly growing hamartomatous lesion in the cerebellum. The kidneys may develop both benign and malignant tumours, though renal cancer occurs less frequently than breast or thyroid malignancies. Vascular abnormalities including arteriovenous malformations have been reported in some cases. The breadth of organ involvement reflects PTEN's fundamental role in regulating cell growth and survival across diverse tissue types.
Risks & severity
The severity of Cowden syndrome varies considerably between individuals, with the benign manifestations typically causing minimal physical impairment whilst the cancer risks represent the primary clinical concern. Lifetime cancer risks are substantially elevated compared to the general population, though exact percentages for individual cancer types are not well established and may vary based on different research cohorts and methodologies. Evidence suggests elevated risks for breast cancer in women, thyroid cancer in both men and women, and endometrial cancer in women over their lifetimes.
Other cancer types occur at increased frequency including renal cell carcinoma and colorectal cancer, though the magnitude of risk elevation for these malignancies is less well defined. Cancers in Cowden syndrome may develop at younger ages than in the general population, with breast cancer sometimes diagnosed in women in their twenties or thirties. The presence of multiple primary cancers in the same individual is not uncommon. Benign manifestations including skin lesions, thyroid nodules, and gastrointestinal polyps generally do not cause significant morbidity, though thyroid nodules may occasionally cause compressive symptoms and require intervention for this reason rather than malignancy concern. The psychosocial impact of living with a hereditary cancer syndrome, managing ongoing surveillance, and making decisions about risk-reducing interventions can be substantial. Severity and specific cancer risks can vary between families carrying different PTEN variants, though predicting individual risk based on genotype remains imperfect. The availability of structured surveillance through NHS cancer genetics services has likely improved outcomes through earlier cancer detection.
Genetic causes
Cowden syndrome is caused by pathogenic variants in the PTEN gene, located on chromosome 10. PTEN encodes a phosphatase enzyme that functions as an essential negative regulator of cellular growth. This protein strips phosphate groups from specific molecular targets within cells, particularly components of the PI3K/AKT signalling cascade. Through this biochemical action, PTEN constrains proliferation signals and blocks pathways that would otherwise promote cell survival.
When disease-causing changes compromise PTEN activity, cells lose this critical constraint, leading to unchecked division and resistance to normal death signals. The consequence is an increased tendency toward both benign overgrowths, seen as hamartomas, and malignant change resulting in cancer. Because PTEN operates across many tissue types throughout the body, loss of its function explains why Cowden syndrome affects multiple organ systems. The enzyme's regulatory role is particularly crucial in tissues subject to frequent cell turnover or responsive to growth stimulation, such as breast epithelium, thyroid follicular cells, and the endometrial lining.
Pathogenic variants in PTEN typically eliminate protein function through mechanisms including nonsense changes, frameshift alterations, and deletions that abolish production of active enzyme. Certain missense changes disrupt amino acids essential for catalytic activity or correct positioning within the cell. A minority of people who satisfy clinical diagnostic criteria for Cowden syndrome lack detectable PTEN variants even after comprehensive genetic analysis, suggesting alternative genetic factors may occasionally produce similar features, or that some pathogenic changes escape detection using current methods. The extent of PTEN impairment may influence how severely the condition manifests, though relationships between specific variants and clinical outcomes remain incompletely characterised.
- PTEN phosphatase and tensin homologPTEN encodes a phosphatase enzyme that regulates cell growth and division, with pathogenic variants causing Cowden syndrome and increased cancer susceptibility.
Inheritance pattern
Cowden syndrome follows an autosomal dominant pattern of inheritance, meaning that a pathogenic variant in just one copy of the PTEN gene is sufficient to cause the condition. Each child of an affected parent has a 50% chance of inheriting the familial pathogenic variant and therefore the predisposition to Cowden syndrome. The condition affects males and females equally in terms of inheritance, though certain cancer risks such as breast and endometrial cancer are specific to women.
A proportion of individuals diagnosed with Cowden syndrome have inherited the condition from an affected parent, whilst others represent de novo variants arising for the first time in that individual. When a pathogenic variant arises de novo, the person's siblings are not at increased risk, but the affected individual can pass the variant to their own children. Family history may appear negative even when a parent carries a PTEN variant if that parent has mild or unrecognised features, as expression of the condition varies considerably. Genetic counselling is recommended for individuals diagnosed with Cowden syndrome and their relatives to clarify inheritance patterns, discuss reproductive options, and facilitate genetic testing for at-risk family members. Predictive testing for adult relatives can inform personalised surveillance strategies, whilst prenatal and preimplantation genetic diagnosis represent options for couples wishing to avoid passing the condition to children, though many families choose not to pursue these given the variable severity and availability of management options.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of Cowden syndrome typically involves a combination of clinical assessment and genetic testing. Clinical diagnostic criteria have been established based on the characteristic constellation of features, categorising findings as pathognomonic, major, or minor criteria. Pathognomonic features include the facial trichilemmomas, acral keratoses, and papillomatous papules. Major criteria encompass breast cancer, thyroid cancer (particularly follicular variant), macrocephaly, and Lhermitte-Duclos disease. A diagnosis can be made clinically when specific combinations of these features are present, though criteria have evolved over time and genetic testing has increasingly become the definitive diagnostic approach.
Genetic testing for pathogenic variants in PTEN is available through NHS clinical genetics services and typically involves sequencing of the entire gene coding region and analysis for deletions or duplications. Testing is usually performed on a blood sample. Individuals meeting clinical criteria or those with strong family histories of features suggestive of Cowden syndrome may be referred for genetic assessment through the NHS Genomic Medicine Service. Within the NHS system, Cowden syndrome testing falls under various R-codes including R207 (Familial breast cancer) and other relevant cancer predisposition panels available through the National Genomic Test Directory. Referral pathways typically involve initial assessment by cancer genetics services, clinical genetics, or occasionally through oncology or other specialist services managing individuals with relevant cancers or features. When a pathogenic PTEN variant is identified in an affected individual, this enables predictive testing for at-risk relatives. Genetic counselling before and after testing helps individuals understand the implications of results, the limitations of testing, and the available management options.
Management & lifestyle
Management of Cowden syndrome centres on cancer surveillance and risk reduction strategies, alongside monitoring of benign manifestations when clinically indicated. Consensus guidelines recommend enhanced breast cancer surveillance for women, typically including annual breast MRI and mammography from age 30-35 years, or earlier if there is a particularly young family history of breast cancer. Some women consider risk-reducing bilateral mastectomy, particularly if they have already developed breast cancer or have strong personal preferences for surgical prevention. Thyroid surveillance through annual ultrasound examination beginning at diagnosis is generally recommended, enabling early detection of thyroid cancer, which often follows an indolent course but benefits from early identification.
For women, endometrial surveillance or risk-reducing hysterectomy may be discussed, particularly from age 40 onwards or after childbearing is complete. Colonoscopy surveillance is recommended, with intervals determined by polyp burden, typically beginning in the late thirties or early forties. Renal imaging surveillance, usually through ultrasound or MRI, is often included in management protocols because of increased kidney cancer risk. Dermatological surveillance allows monitoring of skin lesions, though treatment of benign skin manifestations is generally only pursued for cosmetic or symptomatic reasons. Any surveillance programme requires careful coordination through specialist cancer genetics or clinical genetics services.
Beyond surveillance, lifestyle modifications may contribute to overall cancer risk reduction, though specific evidence for their impact in Cowden syndrome is limited. Maintaining a healthy weight, limiting alcohol consumption, and avoiding smoking represent sensible general health measures. Some individuals with extensive benign thyroid disease require intervention for compressive symptoms rather than malignancy concern. Psychological support and access to genetic counselling remain important throughout life, particularly at key decision points regarding surveillance intensity, risk-reducing surgery, or family planning. Management strategies continue to evolve as evidence accumulates, and individuals should expect their care plans to be reviewed periodically through specialist NHS services. Participation in national audits or research studies may be offered and can contribute to improving future care for this condition.
UK care pathway
Within the NHS, individuals with suspected or confirmed Cowden syndrome are typically managed through specialised cancer genetics or clinical genetics services. Referral pathways may originate from primary care, oncology, or other hospital specialties when characteristic features are recognised or when family history raises suspicion. The National Genomic Test Directory includes relevant testing panels, with Cowden syndrome assessment potentially falling under R207 (Familial breast cancer) and other applicable R-codes depending on the presenting features. Access to genetic testing follows referral to a regional genetics service where clinical geneticists and genetic counsellors assess eligibility based on personal and family history.
Once a molecular diagnosis is confirmed through identification of a pathogenic PTEN variant, ongoing management is coordinated through cancer genetics services, often working collaboratively with breast surgery, endocrinology, gynaecology, and gastroenterology teams. Surveillance protocols are implemented according to national and international consensus guidelines, adapted to individual circumstances. Genetic counselling is offered to affected individuals and at-risk relatives, facilitating informed decision-making about predictive testing, reproductive options, and management strategies. Regional variation may exist in specific service delivery models, but access to specialist genetic services is available across the UK. Individuals diagnosed with Cowden syndrome typically remain under long-term follow-up through these specialist services, ensuring surveillance programmes are maintained and updated as evidence evolves. Support through patient organisations and connection with others affected by the condition can be valuable and may be facilitated through genetics services.
Frequently asked questions
If I have Cowden syndrome, what is my actual risk of developing cancer?
Cancer risks vary between individuals but are substantially elevated compared to the general population. Evidence suggests increased lifetime risks for breast cancer in women, thyroid cancer in both men and women, and endometrial cancer in women. Individual risk assessment through cancer genetics services helps personalise surveillance strategies based on your specific circumstances and family history.
Will the skin bumps from Cowden syndrome go away or can they be removed?
The characteristic skin papules associated with Cowden syndrome are benign and typically persist unless removed. Treatment is generally only pursued for cosmetic reasons or if lesions become irritated. Various removal techniques exist including laser therapy, cryotherapy, or surgical excision, though lesions may recur and complete clearance is often impractical given their number.
How will Cowden syndrome affect my children if I decide to have a family?
Each of your children would have a 50% chance of inheriting the PTEN variant that causes Cowden syndrome. Those who inherit the variant would have the same predisposition as you, though their specific features and cancer risks may differ due to variable expression. Genetic counselling can discuss reproductive options including prenatal diagnosis or preimplantation genetic testing if desired.
Do I need cancer surveillance for life, even if I've never had cancer?
Yes, lifelong surveillance is generally recommended because cancer risks remain elevated throughout life. Surveillance protocols include regular breast imaging, thyroid ultrasound, colonoscopy, and other screening depending on individual risk factors. Your genetics team will coordinate an appropriate surveillance schedule and adjust it as guidelines evolve or your circumstances change.
Should my siblings and other relatives have genetic testing?
First-degree relatives (parents, siblings, children) of someone with a confirmed PTEN variant each have up to a 50% chance of carrying the same variant, depending on whether it was inherited or arose de novo. Genetic testing enables those who carry the variant to access appropriate surveillance, whilst those who test negative can be reassured they do not have elevated risks and cannot pass the condition to their children. Your genetics team can facilitate testing for relatives and provide counselling.
References
- Pilarski R, Burt R, Kohlman W. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. Journal of the National Cancer Institute. 2013. PMID: 24136893
- Takayama T, Muguruma N, Igarashi M. Clinical Guidelines for Diagnosis and Management of Cowden Syndrome/PTEN Hamartoma Tumor Syndrome in Children and Adults-Secondary Publication. Journal of the anus, rectum and colon. 2023. PMID: 37900693
- Garofola C, Jamal Z, Gross GP. Cowden Disease. 2023. PMID: 30252240
- Farooq A, Walker LJ, Bowling J. Cowden syndrome. Cancer treatment reviews. 2010. PMID: 20580873
- Gustafson S, Zbuk KM, Scacheri C. Cowden syndrome. Seminars in oncology. 2007. PMID: 17920899
- Balthazar P, Klontzas ME, Heng LXX. Cowden Syndrome. Radiographics : a review publication of the Radiological Society of North America, Inc. 2022. PMID: 35179988
- Chen HJ, Romigh T, Sesock K. Characterization of cryptic splicing in germline PTEN intronic variants in Cowden syndrome. Human mutation. 2017. PMID: 28677221
- Wadia R. Cowden syndrome. British dental journal. 2021. PMID: 33772192